Westover Capital Advisors LLC Makes New $214,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Westover Capital Advisors LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,107 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.

Several other hedge funds also recently made changes to their positions in TGTX. Bleakley Financial Group LLC acquired a new position in shares of TG Therapeutics in the 4th quarter worth $245,000. Castellan Group acquired a new stake in TG Therapeutics during the 4th quarter worth about $8,539,000. Oppenheimer & Co. Inc. acquired a new stake in TG Therapeutics during the 3rd quarter worth about $759,000. Segall Bryant & Hamill LLC purchased a new stake in TG Therapeutics during the third quarter valued at about $1,225,000. Finally, Barclays PLC boosted its holdings in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after buying an additional 158,323 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TGTX shares. JPMorgan Chase & Co. boosted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Trading Up 3.5 %

TG Therapeutics stock opened at $35.62 on Wednesday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $36.94. The company’s fifty day simple moving average is $30.86 and its 200-day simple moving average is $28.33. The stock has a market cap of $5.54 billion, a P/E ratio of -356.16 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. As a group, sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.